-
My Account
My Account
BSE Live
Apr 16, 16:00Prev. Close
536.80
Open Price
543.00
Bid Price (Qty.)
568.00 (8)
Offer Price (Qty.)
571.90 (300)
NSE Live
Apr 16, 15:59Prev. Close
536.95
Open Price
539.95
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
571.90 (5932)
| Half Yearly Results of Glenmark Pharma (in Rs. Cr.) | Mar '20 | Sep '19 | Mar '19 | Sep '18 | Mar '18 | |
| Net Sales/Income from operations | 3,424.02 | 3,197.86 | 3,130.66 | 3,000.48 | 2,965.57 | |
| Other Operating Income | -- | 90.76 | 88.66 | 85.07 | 258.72 | |
| Total Income From Operations | 3,424.02 | 3,288.61 | 3,219.32 | 3,085.55 | 3,224.29 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 1,165.02 | 1,086.96 | 791.44 | 794.42 | 1,053.72 | |
| Purchase of Traded Goods | 175.76 | 189.49 | 138.51 | 162.79 | 152.46 | |
| Increase/Decrease in Stocks | 38.37 | 10.40 | 314.40 | 157.41 | 4.28 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 506.52 | 565.81 | 456.31 | 513.67 | 487.73 | |
| Depreciation | 73.05 | 65.49 | 52.05 | 54.23 | 59.37 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | -- | -- | -- | -- | -- | |
| R & D Expenses | -- | -- | -- | -- | -- | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | 923.30 | 746.78 | 900.55 | 747.90 | 928.99 | |
| P/L Before Other | 542.01 | 623.69 | 566.05 | 655.15 | 537.74 | |
| Other Income | 345.78 | 261.01 | 83.75 | 391.87 | 81.53 | |
| P/L Before Int. | 887.79 | 884.69 | 649.80 | 1,047.01 | 619.27 | |
| Interest | 123.15 | 133.24 | 107.79 | 116.02 | 97.72 | |
| P/L Before Exceptional Items & Tax | 764.64 | 751.45 | 542.01 | 930.99 | 521.55 | |
| Exceptional Items | 18.55 | -- | -- | 345.19 | -- | |
| P/L Before Tax | 783.19 | 751.45 | 542.01 | 1,276.17 | 521.55 | |
| Tax | 88.48 | 91.62 | 91.30 | 238.58 | 105.92 | |
| P/L After Tax from Ordinary Activities | 694.71 | 659.84 | 450.71 | 1,037.59 | 415.63 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | -- | 26.45 | 107.36 | -- | |
| Net Profit/(Loss) For the Period | 694.71 | 659.84 | 477.16 | 1,144.95 | 415.63 | |
| Equity Share Capital | 28.22 | 28.22 | 28.22 | 28.22 | 28.22 | |
| Reserves Excluding Revaluation Reserves | -- | -- | -- | -- | -- | |
| Equity Dividend Rate (%) | -- | -- | -- | -- | -- | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 24.62 | 23.38 | -- | 40.58 | -- | |
| Diluted EPS | -- | 23.38 | -- | 40.58 | -- | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 24.62 | 23.38 | -- | 40.58 | -- | |
| Diluted EPS. | -- | 23.38 | -- | 40.58 | -- | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | -- | |
| Share Holding (%) | -- | -- | -- | -- | -- | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company). | -- | -- | -- | -- | -- |
17.04.2021
07.04.2021
24.03.2021
Glenmark Pharma share price gains on USFDA nod for Chlorpromazine Hydrochloride tablets
09.03.2021
Glenmark Pharma looking to unlock value of API arm via IPO route in 2021
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015
